These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8047165)

  • 21. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
    Guda K; Claffey KP; Dong M; Nambiar PR; Rosenberg DW
    Mol Carcinog; 2003 May; 37(1):51-9. PubMed ID: 12720300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
    Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipoprotein(a). A potential bridge between the fields of atherosclerosis and thrombosis.
    Scanu AM
    Arch Pathol Lab Med; 1988 Oct; 112(10):1045-7. PubMed ID: 2972266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice.
    Lawn RM; Pearle AD; Kunz LL; Rubin EM; Reckless J; Metcalfe JC; Grainger DJ
    J Biol Chem; 1996 Dec; 271(49):31367-71. PubMed ID: 8940144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques.
    Rossignol P; Luttun A; Martin-Ventura JL; Lupu F; Carmeliet P; Collen D; Anglès-Cano E; Lijnen HR
    J Thromb Haemost; 2006 Mar; 4(3):664-70. PubMed ID: 16460449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9.
    O'Neil CH; Boffa MB; Hancock MA; Pickering JG; Koschinsky ML
    J Biol Chem; 2004 Dec; 279(53):55187-95. PubMed ID: 15498766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A common phenotype associated with atherogenesis in diverse mouse models of vascular lipid lesions.
    Reckless J; Rubin EM; Verstuyft JB; Metcalfe JC; Grainger DJ
    J Vasc Res; 2001; 38(3):256-65. PubMed ID: 11399898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipoprotein(a) induces cell growth in rat peritoneal macrophages through inhibition of transforming growth factor-beta activation.
    Sato Y; Kobori S; Sakai M; Yano T; Higashi T; Matsumura T; Morikawa W; Terano T; Miyazaki A; Horiuchi S; Shichiri M
    Atherosclerosis; 1996 Aug; 125(1):15-26. PubMed ID: 8831923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression.
    Morishita R; Yamada S; Yamamoto K; Tomita N; Kida I; Sakurabayashi I; Kikuchi A; Kaneda Y; Lawn R; Higaki J; Ogihara T
    Circulation; 1998 Nov; 98(18):1898-904. PubMed ID: 9799211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proliferation of human smooth muscle cells promoted by lipoprotein(a).
    Grainger DJ; Kirschenlohr HL; Metcalfe JC; Weissberg PL; Wade DP; Lawn RM
    Science; 1993 Jun; 260(5114):1655-8. PubMed ID: 8503012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The lysine-binding function of Lp(a).
    Boonmark NW; Lawn RM
    Clin Genet; 1997 Nov; 52(5):355-60. PubMed ID: 9520126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration.
    Kojima S; Harpel PC; Rifkin DB
    J Cell Biol; 1991 Jun; 113(6):1439-45. PubMed ID: 1828468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.
    Boonmark NW; Lou XJ; Yang ZJ; Schwartz K; Zhang JL; Rubin EM; Lawn RM
    J Clin Invest; 1997 Aug; 100(3):558-64. PubMed ID: 9239402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response.
    Hoover-Plow J; Hart E; Gong Y; Shchurin A; Schneeman T
    Exp Biol Med (Maywood); 2009 Jan; 234(1):28-34. PubMed ID: 18997104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on the structure and function of the apolipoprotein(a) gene.
    Byrne CD; Lawn RM
    Clin Genet; 1994 Jul; 46(1 Spec No):34-41. PubMed ID: 7988075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cultures of proliferating vascular smooth muscle cells from adult human aorta.
    Kirschenlohr HL; Metcalfe JC; Grainger DJ
    Methods Mol Med; 1996; 2():319-34. PubMed ID: 21359751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kringle-dependent structural and functional polymorphism of apolipoprotein (a).
    Scanu AM; Edelstein C
    Biochim Biophys Acta; 1995 Apr; 1256(1):1-12. PubMed ID: 7742349
    [No Abstract]   [Full Text] [Related]  

  • 38. The apolipoprotein(a) gene: characterization of 5' flanking regions and expression in transgenic mice.
    Lawn RM
    Chem Phys Lipids; 1994 Jan; 67-68():19-23. PubMed ID: 8187213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transforming growth factor-beta and the protection from cardiovascular injury hypothesis.
    Metcalfe JC; Grainger DJ
    Biochem Soc Trans; 1995 May; 23(2):403-6. PubMed ID: 7672431
    [No Abstract]   [Full Text] [Related]  

  • 40. [Apolipoprotein A-IV].
    Kugi M; Sasaki J
    Nihon Rinsho; 2001 Feb; 59 Suppl 2():105-8. PubMed ID: 11351555
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.